ascendis pharma glp-1 receptor agonist weight management diabetes treatments Schematic illustration of monoagonists, dual agonists and triple GLP-1 single, dual, and triple
Description
A thorough medical assessment is essential before starting treatment
Acute cholesterol-lowering effect of exendin-4 in Ldlr-/- and C57BL/6J mice
Substance use, including tobacco, alcohol, opioid, and illicit drug use disorders, should be addressed to maximize GLP-1 benefits
Within the SGLT2i cohort, 47% received empagliflozin, 27% received dapagliflozin and 25% received canagliflozin
